Marcom PK - Search Results

1

Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy.

Shelby RA, Edmond SN, Wren AA, Keefe FJ, Peppercorn JM, Marcom PK, Blackwell KL, Kimmick GG. Shelby RA, et al. Among authors: marcom pk. Support Care Cancer. 2014 Oct;22(10):2851-9. doi: 10.1007/s00520-014-2269-1. Epub 2014 May 13. Support Care Cancer. 2014. PMID: 24821365

2

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.

Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Provenzano E, et al. Mod Pathol. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24. Mod Pathol. 2015. PMID: 26205180 Free article.

3

Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy.

Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK, Blackwell K, Rimer BK. Demark-Wahnefried W, et al. Among authors: marcom pk. J Clin Oncol. 2001 May 1;19(9):2381-9. doi: 10.1200/JCO.2001.19.9.2381. J Clin Oncol. 2001. PMID: 11331316

4

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S. Spector NL, et al. Among authors: marcom pk. J Clin Oncol. 2005 Apr 10;23(11):2502-12. doi: 10.1200/JCO.2005.12.157. Epub 2005 Jan 31. J Clin Oncol. 2005. PMID: 15684311 Clinical Trial.

5

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL. Burris HA 3rd, et al. Among authors: marcom pk. J Clin Oncol. 2005 Aug 10;23(23):5305-13. doi: 10.1200/JCO.2005.16.584. Epub 2005 Jun 13. J Clin Oncol. 2005. PMID: 15955900 Clinical Trial.

6

Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy.

Dressman HK, Hans C, Bild A, Olson JA, Rosen E, Marcom PK, Liotcheva VB, Jones EL, Vujaskovic Z, Marks J, Dewhirst MW, West M, Nevins JR, Blackwell K. Dressman HK, et al. Among authors: marcom pk. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):819-26. doi: 10.1158/1078-0432.CCR-05-1447. Clin Cancer Res. 2006. PMID: 16467094

7

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.

Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL, Anders C, Devi GR, Lyerly HK, Clay TM. Morse MA, et al. Among authors: marcom pk. J Transl Med. 2007 Sep 6;5:42. doi: 10.1186/1479-5876-5-42. J Transl Med. 2007. PMID: 17822557 Free PMC article. Clinical Trial.

8

A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.

Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, Lyons P, Behera M, Copland S, Kimmick G, Shaw H, Snyder S, Antenos M, Woodruff T, Blackwell K. Anders C, et al. Among authors: marcom pk. Cancer Invest. 2008 Apr-May;26(3):286-95. doi: 10.1080/07357900701829777. Cancer Invest. 2008. PMID: 18317970 Free PMC article.

9

Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy.

Demark-Wahnefried W, Case LD, Blackwell K, Marcom PK, Kraus W, Aziz N, Snyder DC, Giguere JK, Shaw E. Demark-Wahnefried W, et al. Among authors: marcom pk. Clin Breast Cancer. 2008 Feb;8(1):70-9. doi: 10.3816/CBC.2008.n.005. Clin Breast Cancer. 2008. PMID: 18501061 Clinical Trial.

10

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL. Anders CK, et al. Among authors: marcom pk. J Clin Oncol. 2008 Jul 10;26(20):3324-30. doi: 10.1200/JCO.2007.14.2471. J Clin Oncol. 2008. PMID: 18612148

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124 results

Search Page

Filters